BPC-157 (Oral) vs Pentosan Polysulfate
A side-by-side research comparison of BPC-157 (Oral) and Pentosan Polysulfate across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | Pentosan Polysulfate |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Pentosan Polysulfate Sodium |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | FDA Approved |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | Acts as a glycosaminoglycan analog that coats bladder mucosa, inhibits complement activation, and stimulates proteoglycan synthesis in cartilage. |
| Molecular weight | 1419.53 Da | 4000-6000 Da (average) |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | ~24 hours |
| Bioavailability | ~40-60% oral (arginate salt form) | ~3-6% oral; higher via injection |
| Typical dose | 500 mcg - 1 mg | 100 mg |
| Frequency | 1-2x daily | 3x daily (oral) |
| Route | Oral capsule (arginate salt) | Oral or subcutaneous injection |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
Pentosan Polysulfate reported benefits
- Bladder wall protection
- Cartilage repair support
- Anti-inflammatory action
- Joint pain reduction
Related comparisons
Research and educational reference only. Not medical advice.